Alternatively, in non-inflammatory conditions, mutations in genes such as epidermal growth factor receptor (EGFR) can modulate signaling pathways, leading tumor cells to produce chemokines like CCL22 that enhance Tregs infiltration (77). This evidence concerns the gene EGFR and neoplasm.